Curemark concludes patient recruitment in autism drug trial
Curemark said it has reached its target of enrolling 170 patients in this autism drug trial. Curemark medical director Bill Gannon said they have been extremely pleased with
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.